For the month of June 2025

 

 

(Translation of registrant’s name into English)

 

(Address of principal executive offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

Form 20-F ☒

Form 40-F ☐

 

 

Exhibit Number	Description
99.1	03 June 2025- “Director/PDMR Shareholding”

 

 

 

 

99.1

 

Haleon plc: Director/PDMR Shareholding 

​ 

3 June 2025: Haleon plc (the "Company" or "Haleon") (LSE/NYSE:HLN) today announces notification and public disclosure in accordance with the requirements of The UK Market Abuse Regulation of Transactions by Persons Discharging Managerial Responsibilities ("PDMRs").

 

On 2 June 2025, Ed Petter, Chief Corporate Affairs Officer, received the vesting of the first tranche of an award of Haleon Ordinary Shares under the Haleon Share Value Plan. The award was granted as part of his remuneration arrangements upon joining Haleon, to compensate for forfeited incentives from his previous employment.

 

The award is subject to malus and clawback provisions.

 

Further details are set out in the below notification, made in accordance with the requirements of The UK Market Abuse Regulations. 

 

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Ed Petter
2	Reason for the notification
a)	Position/status	Chief Corporate Affairs Officer
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Haleon plc
b)	LEI	549300PSB3WWEODCUP19
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument     Identification code	Ordinary Shares of £0.01 each   GB00BMX86B70
b)	Nature of the transaction	Acquisition of Ordinary Shares in respect of the first vesting of the Haleon plc Share Value Plan (Buyout award).
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		Nil	51,584
d)	Aggregated information    - Aggregated volume    - Price	N/A
e)	Date of the transaction	2 June 2025
f)	Place of the transaction	Outside a trading venue
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument     Identification code	Ordinary Shares of £0.01 each   GB00BMX86B70
b)	Nature of the transaction	Automatic disposal of Ordinary Shares resulting from Haleon plc Share Value Plan (Buyout award) vesting to cover tax liabilities.
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£4.134623	24,305.243108
d)	Aggregated information     - Aggregated volume    - Price	N/A
e)	Date of the transaction	2 June 2025
f)	Place of the transaction	London Stock Exchange (XLON)

 

 

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

 

For more information, please visit www.haleon.com. 

 

 

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

		HALEON PLC (Registrant)
Date: June 03, 2025	By:	/s/ Amanda Mellor
		Name:	Amanda Mellor
		Title:	Company Secretary